IDH2 and central nervous system cancer: The mutated IDH pathway represents a possible target for novel glioma therapies, and, as such, there has begun a significant shift towards development of imaging strategies for the reliable longitudinal assessment and quantification of 2-HG levels during treatment and throughout clinical trials.